Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Kentaro Ohara, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranai, Yasuharu Akasaki, et al. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathology. 2024. 41. 2. 61-72
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, et al. 10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT. Neuro-Oncology Advances. 2023. 5. Supplement_5. v1-v1
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Yohei Yamamoto, Ryotaro Imai, Yuki Kuranai, Kyoichi Tohmoto, Yuzuru Hasegawa, et al. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. 2023
Jun Takei, Yuko Kamata, Toshihide Tanaka, Nei Fukasawa, Kazutaka Gomisawa, Mari Satake, Ryosuke Mori, Yohei Yamamoto, Tomoya Suzuki, Ayaka Oda, et al. Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII. 2023
Tomoya Suzuki, Jun Takei, Nei Fukasawa, Kenta Suzuki, Daisuke Ogawa, Yohei Yamamoto, Yasuharu Akasaki, Yuichi Murayama, Masayuki Shimoda, Keisuke Miyake, et al. FMISO-PET and immunohistochemistry verified tumor oxygenation, stemness, and immunosupportive microenvironment after preoperative neoadjuvant bevacizumab for newly diagnosed glioblastoma. World neurosurgery. 2023. 175. e1364-e1374
Yamamoto Y, Tanaka T, Takei J, Teshigawara A, Nawate S, Tohmoto K, Ishii T, Hasegawa Y, Akasaki Y, Murayama Y. MET-2 Clinical features of renal cell carcinoma brain metastases compared with other carcinomas. Neuro-Oncology Advances. 2023. 5. 5. v4-v4
Akasaki Y, Takei J, Yamamoto Y, Tanaka T, Teshigawara A, Kamata Y, Ohara K, Nawate S, Suzuki T, Yanagisawa T, et al. IMT-1 A role of dendritic cell immunotherapy as a modality in multidisciplinary therapy for glioblastoma. Neuro-Oncology Advances. 2023. 5. 5. v3-v4
Ezaki T, Tanaka T, Tamura R, Yamamoto Y, Takei J, Morimoto Y, Imai R, Kuranari Y, Akasaki Y, Murayama Y, et al. ANGI-1 Regulation of alternative angiogenic factors in bevacizumab therapy for glioblastoma. Neuro-Oncology Advances. 2023. 5. 5. v1-v2
Akasaki Y, Suzuki T, Takei J, Tanaka T, Mori R, Koseki H, Yamamoto Y, Teshigawara A, Kamata Y, Yanagisawa T, et al. Pros and cons of surgical intervention for diffuse midline glioma aimed at dendritic cell immunotherapy. Neuro-Oncology Advances. 2022. 4. 3. iii12
Tohmoto K, Yamamoto Y, Tanaka T, Suzuki T, Teshigawara A, Takei J, Koseki H, Mori R, Akasaki Y, Murayama Y. Clinical benefit of add-on bevacizumab for newly diagnosed glioblastoma in elderly patients with unresectable and poor performance status. Neuro-Oncology Advances. 2022. 4. 3. iii8
Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to the Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas.
(The 40th Annual Meeting of the Japan Society for Neuro-Oncology 2022)
Low expression of HLA-A as a novel prognostic factor in glioblastoma treated with tumor fused dendritic cell vaccines
(27th Annual Meeting Society of Neuro-Oncology 2022)
Survival outcome and prognostic factors in patients with IDH-wild type glioblastoma treated with dendritic cell and tumor cell vaccines.
(The 81th Annual Meeting of the Japan Neurosurgical society 2022)
Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas
(The 61th Annual Meeting of the Neuro-Oncologist 2022)
2012/04 - 現在 Jikei University School of Medicine Neurosurgery
Awards (1)：
2020/09 - the 71st Annual Meeting of the German Society of Neurosurgery& 9th Joint Meeting with the Japan Neurosurgical Society Young Traveler Award Gene expression profile of glioblastoma cells from patients with long-term survival treated with dendritic cell immunotherapy,
Association Membership(s) (9)：
American Association for Cancer Research
, Japanese Cancer Association
, Society of Neuro-Oncology
, Japan Society for Neuro-Oncology
, Japanese Board of Cancer Therapy
, Japanese Society of Neuroendoscopy
, Neurospinal Society of Japan
, Japanese Society for Neuroendovascular Therapy
, Japan Neurosurgical Society
